Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All lactoferrin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchLactoferrinLactoferrin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: a double-blinded randomized clinical trial (LF-COVID)

Navarro et al., BioMetals, doi:10.1007/s10534-022-00477-3, LF-COVID, NCT04526821
Dec 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Symp. case -59% Improvement Relative Risk Case -23% Lactoferrin  LF-COVID  Prophylaxis  DB RCT Is prophylaxis with lactoferrin beneficial for COVID-19? Double-blind RCT 209 patients in Peru (October 2020 - February 2021) More symptomatic cases with lactoferrin (not stat. sig., p=0.34) c19early.org Navarro et al., BioMetals, December 2022 Favorslactoferrin Favorscontrol 0 0.5 1 1.5 2+
Early terminated low-risk patient prophylaxis RCT in Peru, showing no significant difference in cases with lactoferrin. There were no moderate or severe cases.
risk of symptomatic case, 58.7% higher, RR 1.59, p = 0.34, treatment 11 of 104 (10.6%), control 7 of 105 (6.7%).
risk of case, 23.4% higher, RR 1.23, p = 0.65, treatment 11 of 104 (10.6%), control 9 of 105 (8.6%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Navarro et al., 7 Dec 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Peru, peer-reviewed, median age 37.0, 14 authors, study period October 2020 - February 2021, trial NCT04526821 (history) (LF-COVID). Contact: theresa.ochoa@upch.pe.
This PaperLactoferrinAll
Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: a double-blinded randomized clinical trial (LF-COVID)
Rafaella Navarro, Jose Luis Paredes, Lourdes Tucto, Carlos Medina, Eddie Angles-Yanqui, Juan Carlos Nario, Jorge Ruiz-Cabrejos, Juan Luis Quintana, Kevin Turpo-Espinoza, Fernando Mejia-Cordero, Meylin Aphang-Lam, Jorge Florez, Gabriel Carrasco-Escobar, Theresa Jean Ochoa
BioMetals, doi:10.1007/s10534-022-00477-3
suspected episodes. A serological test was obtained from all participants at the end of the intervention. The main outcome included symptomatic and asymptomatic cases. A sub-analysis explored the time to symptomatic infection. Secondary outcomes were the severity, frequency, and duration of symptomatic infection. The study was prematurely cancelled due to the availability of vaccines against SARS-CoV-2 in Peru. 209 participants were enrolled and randomized, 104 received bLF and 105 placebo. SARS-CoV-2 infection occurred in 11 (10.6%) participants assigned to bLF and in 9 (8.6%) participants assigned to placebo without significant differences (Incidence Rate Ratio = 1.23, 95%CI 0.51-3.06, p-value = 0.64). There was no significant effect of bLF on time to symptomatic infection (Hazard Ratio = 1.61, 95%CI 0.62-4.19, p-value = 0.3). There were no significant Abstract Lactoferrin (LF) has in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to determine the effect of bovine lactoferrin (bLF) in the prevention of SARS-CoV-2 infection in health care personnel. A randomized, double-blinded, placebo-controlled clinical trial was conducted in two tertiary hospitals that provide care to patients with SARS-CoV-2 infection in Lima, Peru. Daily supplementation with 600 mg of enteral bLF versus placebo for 90 days was compared. Participants were weekly screened for symptoms suggestive of SARS-CoV-2 infection and molecular testing was performed on
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s10534-022-00477-3. Duration and prevalence of secondary outcomes are shown in Table 3 . The most common symptoms among the 18 symptomatic SARS-CoV-2 infections were: cough in 11 participants (61%), nasal secretion in 10 (56%), headache in 8 (44%), and sore throat in 8 (44%). The proportion of patients who developed fever during the study period and the duration of fever were slightly lower t in bLF than in the placebo group, but not significant different (Table 3 ).
References
Alugupalli, Kalfas, Degradation of lactoferrin by periodontitis-associated bacteria, FEMS Microbiol Lett, doi:10.1111/j.1574-6968.1996.tb08579.x
Beljaars, Van Der Strate, Bakker, Reker-Smit, Van Loenen-Weemaes et al., Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo, Antivir Res, doi:10.1111/j.1574-6968.1996.tb08579.x
Berlutti, Schippa, Morea, Sarli, Perfetto et al., Lactoferrin downregulates proinflammatory cytokines upexpressed in intestinal epithelial cells infected with invasive or noninvasive Escherichia coli strains, Biochem Cell Biol
Berthon, Williams, Williams, Wood, Effect of lactoferrin supplementation on inflammation, immune function, and prevention of respiratory tract infections in humans: a systematic review and meta-analysis, Adv Nutr, doi:10.1093/advances/nmac047
Biase, Pietrantoni, Tinari, Siciliano, Valenti et al., Heparin-interacting sites of bovine lactoferrin are involved in anti-adenovirus activity, J Med Virol
Chang, Ng, Sun, Lactoferrin as potential preventative and adjunct treatment for COVID-19, Int J Antimicrob Agents
Chen, Chai, Li, Zhang, Xie et al., Effect of bovine lactoferrin from iron-fortified formulas on diarrhea and respiratory tract infections of weaned infants in a randomized controlled trial, Nutrition
Drobni, Näslund, Evander, Lactoferrin inhibits human papillomavirus binding and uptake in vitro, Antivir Res
Figueroa, Bottazzi, Hotez, Batista, Ergonul et al., Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics, Lancet
Hanson, Caliendo, Arias, Englund, Lee et al., ica guidelines on the diagnosis of COVID-19, Infectious Diseases Society of Amer
Harris, Taylor, Minor, Elliott, Fernandez et al., The REDCap consortium: building an international community of software platform partners, J Biomed Inform
Harris, Taylor, Thielke, Payne, Gonzalez et al., Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform
Ishikawa, Awano, Fukui, Sasaki, Kyuwa, The protective effects of lactoferrin against murine norovirus infection through inhibition of both viral attachment and replication, Biochem Biophys Res Commun
Lang, Yang, Deng, Liu, Yang et al., Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans, PLoS ONE
Legrand, Overview of lactoferrin as a natural immune modulator, J Pediatr
Lizzi, Carnicelli, Clarkson, Bovine lactoferrin and its tryptic peptides: antibacterial activity against different species, Appl Biochem Microbiol, doi:10.1134/S0003683816040116
Marchetti, Trybala, Superti, Johansson, Bergström, Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans, Virology
Oda, Wakabayashi, Tanaka, Yamauchi, Sugita et al., Effects of lactoferrin on infectious diseases in Japanese summer: a randomized, double-blinded, placebo-controlled trial, J Microbiol Immunol Infect, doi:10.1016/j.jmii.2020.02.010
Reghunathan, Jayapal, Hsu, Chng, Tai et al., Expression profile of immune response genes in patients with severe acute respiratory syndrome, BMC Immunol
Serrano, Kochergina, Albors, Diaz, Oroval et al., Liposomal lactoferrin as potential preventative and cure for COVID-19, Int J Res Health Sci
Shah, Wood, Gribben, Caldwell, Bishop et al., Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study, doi:10.1136/bmj.m3582
Superti, Siciliano, Rega, Giansanti, Valenti et al., Involvement of bovine lactoferrin metal saturation, sialic acid and protein fragments in the inhibition of rotavirus infection, Biochim Biophys Acta
Vitetta, Coulson, Beck, Gramotnev, Du et al., The clinical efficacy of a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) for the common cold: a double blind randomized study, Complement Ther Med
{ 'indexed': {'date-parts': [[2022, 12, 8]], 'date-time': '2022-12-08T15:13:48Z', 'timestamp': 1670512428615}, 'reference-count': 25, 'publisher': 'Springer Science and Business Media LLC', 'license': [ { 'start': { 'date-parts': [[2022, 12, 7]], 'date-time': '2022-12-07T00:00:00Z', 'timestamp': 1670371200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.springernature.com/gp/researchers/text-and-data-mining'}, { 'start': { 'date-parts': [[2022, 12, 7]], 'date-time': '2022-12-07T00:00:00Z', 'timestamp': 1670371200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://www.springernature.com/gp/researchers/text-and-data-mining'}], 'funder': [ { 'DOI': '10.13039/501100009583', 'name': 'Morinaga Foundation For Health and Nutrition', 'doi-asserted-by': 'publisher'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'DOI': '10.1007/s10534-022-00477-3', 'type': 'journal-article', 'created': {'date-parts': [[2022, 12, 7]], 'date-time': '2022-12-07T02:02:51Z', 'timestamp': 1670378571000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: a ' 'double-blinded randomized clinical trial (LF-COVID)', 'prefix': '10.1007', 'clinical-trial-number': [ { 'clinical-trial-number': 'nct04526821', 'registry': '10.18810/clinical-trials-gov'}], 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-6099-7509', 'authenticated-orcid': False, 'given': 'Rafaella', 'family': 'Navarro', 'sequence': 'first', 'affiliation': []}, {'given': 'Jose Luis', 'family': 'Paredes', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lourdes', 'family': 'Tucto', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carlos', 'family': 'Medina', 'sequence': 'additional', 'affiliation': []}, {'given': 'Eddie', 'family': 'Angles-Yanqui', 'sequence': 'additional', 'affiliation': []}, {'given': 'Juan Carlos', 'family': 'Nario', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jorge', 'family': 'Ruiz-Cabrejos', 'sequence': 'additional', 'affiliation': []}, {'given': 'Juan Luis', 'family': 'Quintana', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kevin', 'family': 'Turpo-Espinoza', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fernando', 'family': 'Mejia-Cordero', 'sequence': 'additional', 'affiliation': []}, {'given': 'Meylin', 'family': 'Aphang-Lam', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jorge', 'family': 'Florez', 'sequence': 'additional', 'affiliation': []}, {'given': 'Gabriel', 'family': 'Carrasco-Escobar', 'sequence': 'additional', 'affiliation': []}, {'given': 'Theresa Jean', 'family': 'Ochoa', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2022, 12, 7]]}, 'reference': [ { 'issue': '2', 'key': '477_CR1', 'doi-asserted-by': 'publisher', 'first-page': '209', 'DOI': '10.1111/j.1574-6968.1996.tb08579.x', 'volume': '145', 'author': 'KR Alugupalli', 'year': '1996', 'unstructured': 'Alugupalli KR, Kalfas S (1996) Degradation of lactoferrin by ' 'periodontitis-associated bacteria. FEMS Microbiol Lett 145(2):209–214. ' 'https://doi.org/10.1111/j.1574-6968.1996.tb08579.x', 'journal-title': 'FEMS Microbiol Lett'}, { 'issue': '3', 'key': '477_CR2', 'doi-asserted-by': 'publisher', 'first-page': '197', 'DOI': '10.1016/j.antiviral.2004.05.002', 'volume': '63', 'author': 'L Beljaars', 'year': '2004', 'unstructured': 'Beljaars L, Van Der Strate BWA, Bakker HI, Reker-Smit C, Van ' 'Loenen-Weemaes AM, Wiegmans FC et al (2004) Inhibition of ' 'cytomegalovirus infection by lactoferrin in vitro and in vivo. Antivir ' 'Res 63(3):197–208', 'journal-title': 'Antivir Res'}, { 'key': '477_CR3', 'doi-asserted-by': 'publisher', 'first-page': '351', 'DOI': '10.1139/o06-039', 'volume': '84', 'author': 'F Berlutti', 'year': '2006', 'unstructured': 'Berlutti F, Schippa S, Morea C, Sarli S, Perfetto B, Donnarumma G et al ' '(2006) Lactoferrin downregulates pro-inflammatory cytokines upexpressed ' 'in intestinal epithelial cells infected with invasive or noninvasive ' 'Escherichia coli strains. Biochem Cell Biol 84:351–7', 'journal-title': 'Biochem Cell Biol'}, { 'key': '477_CR4', 'doi-asserted-by': 'publisher', 'author': 'BS Berthon', 'year': '2022', 'unstructured': 'Berthon BS, Williams LM, Williams EJ, Wood LG (2022) Effect of ' 'lactoferrin supplementation on inflammation, immune function, and ' 'prevention of respiratory tract infections in humans: a systematic ' 'review and meta-analysis. Adv Nutr. ' 'https://doi.org/10.1093/advances/nmac047', 'journal-title': 'Adv Nutr', 'DOI': '10.1093/advances/nmac047'}, { 'issue': '3', 'key': '477_CR5', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijantimicag.2020.106118', 'volume': '56', 'author': 'R Chang', 'year': '2020', 'unstructured': 'Chang R, Ng TB, Sun WZ (2020) Lactoferrin as potential preventative and ' 'adjunct treatment for COVID-19. Int J Antimicrob Agents 56(3):106118', 'journal-title': 'Int J Antimicrob Agents'}, { 'issue': '2', 'key': '477_CR6', 'doi-asserted-by': 'publisher', 'first-page': '222', 'DOI': '10.1016/j.nut.2015.08.010', 'volume': '32', 'author': 'K Chen', 'year': '2016', 'unstructured': 'Chen K, Chai L, Li H, Zhang Y, Xie HM, Shang J et al (2016) Effect of ' 'bovine lactoferrin from iron-fortified formulas on diarrhea and ' 'respiratory tract infections of weaned infants in a randomized ' 'controlled trial. Nutrition 32(2):222–227', 'journal-title': 'Nutrition'}, { 'key': '477_CR7', 'unstructured': 'COVID-19 Map—Johns Hopkins Coronavirus Resource Center. ' 'https://coronavirus.jhu.edu/map.html. Accessed 2 May 2021'}, { 'issue': '4', 'key': '477_CR8', 'doi-asserted-by': 'publisher', 'first-page': '495', 'DOI': '10.1002/jmv.10337', 'volume': '69', 'author': 'AM Di Biase', 'year': '2003', 'unstructured': 'Di Biase AM, Pietrantoni A, Tinari A, Siciliano R, Valenti P, Antonini G ' 'et al (2003) Heparin-interacting sites of bovine lactoferrin are ' 'involved in anti-adenovirus activity. J Med Virol 69(4):495–502', 'journal-title': 'J Med Virol'}, { 'issue': '1', 'key': '477_CR9', 'doi-asserted-by': 'publisher', 'first-page': '63', 'DOI': '10.1016/j.antiviral.2004.05.005', 'volume': '64', 'author': 'P Drobni', 'year': '2004', 'unstructured': 'Drobni P, Näslund J, Evander M (2004) Lactoferrin inhibits human ' 'papillomavirus binding and uptake in vitro. Antivir Res 64(1):63–68', 'journal-title': 'Antivir Res'}, { 'key': '477_CR10', 'doi-asserted-by': 'publisher', 'first-page': '562', 'DOI': '10.1016/S0140-6736(21)00242-7', 'volume': '397', 'author': 'JP Figueroa', 'year': '2021', 'unstructured': 'Figueroa JP, Bottazzi ME, Hotez P, Batista C, Ergonul O, Gilbert S et al ' '(2021) Urgent needs of low-income and middle-income countries for ' 'COVID-19 vaccines and therapeutics. Lancet 397:562–564', 'journal-title': 'Lancet'}, { 'key': '477_CR11', 'doi-asserted-by': 'crossref', 'unstructured': 'Hanson KE, Caliendo AM, Arias CA, Englund JA, Lee MJ, Loeb M et al ' '(2020) Infectious Diseases Society of America guidelines on the ' 'diagnosis of COVID-19. www.idsociety.org/COVID19guidelines/dx. Accessed ' '29 June 2021', 'DOI': '10.1093/cid/ciab048'}, { 'issue': '2', 'key': '477_CR12', 'doi-asserted-by': 'publisher', 'first-page': '377', 'DOI': '10.1016/j.jbi.2008.08.010', 'volume': '42', 'author': 'PA Harris', 'year': '2009', 'unstructured': 'Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) ' 'Research electronic data capture (REDCap)—a metadata-driven methodology ' 'and workflow process for providing translational research informatics ' 'support. J Biomed Inform 42(2):377–381', 'journal-title': 'J Biomed Inform'}, { 'key': '477_CR13', 'doi-asserted-by': 'publisher', 'first-page': '103208', 'DOI': '10.1016/j.jbi.2019.103208', 'volume': '95', 'author': 'PA Harris', 'year': '2019', 'unstructured': 'Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L et al ' '(2019) The REDCap consortium: building an international community of ' 'software platform partners. J Biomed Inform 95:103208', 'journal-title': 'J Biomed Inform'}, { 'issue': '4', 'key': '477_CR14', 'doi-asserted-by': 'publisher', 'first-page': '791', 'DOI': '10.1016/j.bbrc.2013.04.013', 'volume': '434', 'author': 'H Ishikawa', 'year': '2013', 'unstructured': 'Ishikawa H, Awano N, Fukui T, Sasaki H, Kyuwa S (2013) The protective ' 'effects of lactoferrin against murine norovirus infection through ' 'inhibition of both viral attachment and replication. Biochem Biophys Res ' 'Commun 434(4):791–796', 'journal-title': 'Biochem Biophys Res Commun'}, { 'issue': '8', 'key': '477_CR15', 'doi-asserted-by': 'publisher', 'first-page': '23710', 'DOI': '10.1371/journal.pone.0023710', 'volume': '6', 'author': 'J Lang', 'year': '2011', 'unstructured': 'Lang J, Yang N, Deng J, Liu K, Yang P, Zhang G et al (2011) Inhibition ' 'of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate ' 'proteoglycans. PLoS ONE 6(8):23710', 'journal-title': 'PLoS ONE'}, { 'key': '477_CR16', 'doi-asserted-by': 'publisher', 'first-page': 'S10', 'DOI': '10.1016/j.jpeds.2016.02.071', 'volume': '173', 'author': 'D Legrand', 'year': '2016', 'unstructured': 'Legrand D (2016) Overview of lactoferrin as a natural immune modulator. ' 'J Pediatr 173:S10–S15', 'journal-title': 'J Pediatr'}, { 'key': '477_CR17', 'doi-asserted-by': 'publisher', 'first-page': '435', 'DOI': '10.1134/S0003683816040116', 'volume': '52', 'author': 'AR Lizzi', 'year': '2016', 'unstructured': 'Lizzi AR, Carnicelli V, Clarkson MM et al (2016) Bovine lactoferrin and ' 'its tryptic peptides: antibacterial activity against different species. ' 'Appl Biochem Microbiol 52:435–440. ' 'https://doi.org/10.1134/S0003683816040116', 'journal-title': 'Appl Biochem Microbiol'}, { 'issue': '1', 'key': '477_CR18', 'doi-asserted-by': 'publisher', 'first-page': '405', 'DOI': '10.1016/j.virol.2003.09.029', 'volume': '318', 'author': 'M Marchetti', 'year': '2004', 'unstructured': 'Marchetti M, Trybala E, Superti F, Johansson M, Bergström T (2004) ' 'Inhibition of herpes simplex virus infection by lactoferrin is dependent ' 'on interference with the virus binding to glycosaminoglycans. Virology ' '318(1):405–413', 'journal-title': 'Virology'}, { 'key': '477_CR19', 'doi-asserted-by': 'publisher', 'author': 'H Oda', 'year': '2020', 'unstructured': 'Oda H, Wakabayashi H, Tanaka M, Yamauchi K, Sugita C, Yoshida H et al ' '(2020) Effects of lactoferrin on infectious diseases in Japanese summer: ' 'a randomized, double-blinded, placebo-controlled trial. J Microbiol ' 'Immunol Infect. https://doi.org/10.1016/j.jmii.2020.02.010', 'journal-title': 'J Microbiol Immunol Infect', 'DOI': '10.1016/j.jmii.2020.02.010'}, { 'issue': '1', 'key': '477_CR20', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1186/1471-2172-6-2', 'volume': '6', 'author': 'R Reghunathan', 'year': '2005', 'unstructured': 'Reghunathan R, Jayapal M, Hsu LY, Chng HH, Tai D, Leung BP et al (2005) ' 'Expression profile of immune response genes in patients with severe ' 'acute respiratory syndrome. BMC Immunol 6(1):1–11', 'journal-title': 'BMC Immunol'}, { 'issue': '1', 'key': '477_CR21', 'first-page': '08', 'volume': '8', 'author': 'G Serrano', 'year': '2020', 'unstructured': 'Serrano G, Kochergina I, Albors A, Diaz E, Oroval M, Hueso G et al ' '(2020) Liposomal lactoferrin as potential preventative and cure for ' 'COVID-19. Int J Res Health Sci 8(1):08–15', 'journal-title': 'Int J Res Health Sci'}, { 'key': '477_CR22', 'doi-asserted-by': 'publisher', 'author': 'ASV Shah', 'year': '2020', 'unstructured': 'Shah ASV, Wood R, Gribben C, Caldwell D, Bishop J, Weir A et al (2020) ' 'Risk of hospital admission with coronavirus disease 2019 in healthcare ' 'workers and their households: nationwide linkage cohort study. BMJ. ' 'https://doi.org/10.1136/bmj.m3582', 'journal-title': 'BMJ', 'DOI': '10.1136/bmj.m3582'}, { 'issue': '2–3', 'key': '477_CR23', 'doi-asserted-by': 'publisher', 'first-page': '107', 'DOI': '10.1016/S0304-4165(01)00178-7', 'volume': '1528', 'author': 'F Superti', 'year': '2001', 'unstructured': 'Superti F, Siciliano R, Rega B, Giansanti F, Valenti P, Antonini G ' '(2001) Involvement of bovine lactoferrin metal saturation, sialic acid ' 'and protein fragments in the inhibition of rotavirus infection. Biochim ' 'Biophys Acta 1528(2–3):107–115', 'journal-title': 'Biochim Biophys Acta'}, { 'issue': '3', 'key': '477_CR24', 'doi-asserted-by': 'publisher', 'first-page': '164', 'DOI': '10.1016/j.ctim.2012.12.006', 'volume': '21', 'author': 'L Vitetta', 'year': '2013', 'unstructured': 'Vitetta L, Coulson S, Beck SL, Gramotnev H, Du S, Lewis S (2013) The ' 'clinical efficacy of a bovine lactoferrin/whey protein Ig-rich fraction ' '(Lf/IgF) for the common cold: a double blind randomized study. ' 'Complement Ther Med 21(3):164–171', 'journal-title': 'Complement Ther Med'}, { 'key': '477_CR25', 'unstructured': 'World Health Organization (WHO) (2021) COVID-19 clinical management: ' 'living guidance. ' 'https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1. ' 'Accessed 16 May 2021'}], 'container-title': 'BioMetals', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s10534-022-00477-3.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s10534-022-00477-3/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s10534-022-00477-3.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 12, 8]], 'date-time': '2022-12-08T14:29:57Z', 'timestamp': 1670509797000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s10534-022-00477-3'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 12, 7]]}, 'references-count': 25, 'alternative-id': ['477'], 'URL': 'http://dx.doi.org/10.1007/s10534-022-00477-3', 'relation': {}, 'ISSN': ['0966-0844', '1572-8773'], 'subject': [ 'Metals and Alloys', 'General Agricultural and Biological Sciences', 'General Biochemistry, Genetics and Molecular Biology', 'Biomaterials'], 'container-title-short': 'Biometals', 'published': {'date-parts': [[2022, 12, 7]]}, 'assertion': [ { 'value': '30 March 2022', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '24 November 2022', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '7 December 2022', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'All authors have no conflict of interest.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Conflict of interest'}}, { 'value': 'This content has been made available to all.', 'name': 'free', 'label': 'Free to read'}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit